ESR1 and breast carcinoma: Endoxifen, a tamoxifen metabolite, is a potent antiestrogen that functions, in a concentration-dependent manner, by targeting ERα for degradation by the proteasome, blocking ERα-mediated transcriptional activation, and inhibiting estrogen-induced breast cancer cell proliferation [24].